// App-Quantinova.ai

581 : Use of a Fc-Optimized CD19 Antibody for Treatment of MRD in Pediatric Patients with B-Lineage Acute Lymphoblastic Leukemia

Researchers

Presenter

  • Heiko-Manuel Teltschik

Principal Investigators

  • Patrick Schlegel

  • Rupert Handgretinger

  • Ursula Seidel

  • Ludger Grosse-Hovest

  • Steffen Aulwurm

  • Martin Hofmann

  • Rouwen Teltschik

  • Kai Witte

  • Hans-Georg Rammensee

  • Gundram Jung

Medical Centers

  • Department of Neurosurgery, Eberhard Karls University, Tubingen, Germany

  • Hematology / Oncology, University Childrens Hospital, Graz, Austria

Locations

  • Germany

Companies

  • N/A

Study Components

Therapeutic Area

  • Genetic Disorder

  • Blood/haematological Diseases

Disease

  • Acute lymphoblastic leukemia

  • Scott syndrome

Biomarkers

  • Natural Killer cells

  • Breakpoint Cluster Region

Drug/Treatment

  • N/A

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Interim

Copyright © 2026. QuantiNova All rights reserved